<code id='A1F1C8AA97'></code><style id='A1F1C8AA97'></style>
    • <acronym id='A1F1C8AA97'></acronym>
      <center id='A1F1C8AA97'><center id='A1F1C8AA97'><tfoot id='A1F1C8AA97'></tfoot></center><abbr id='A1F1C8AA97'><dir id='A1F1C8AA97'><tfoot id='A1F1C8AA97'></tfoot><noframes id='A1F1C8AA97'>

    • <optgroup id='A1F1C8AA97'><strike id='A1F1C8AA97'><sup id='A1F1C8AA97'></sup></strike><code id='A1F1C8AA97'></code></optgroup>
        1. <b id='A1F1C8AA97'><label id='A1F1C8AA97'><select id='A1F1C8AA97'><dt id='A1F1C8AA97'><span id='A1F1C8AA97'></span></dt></select></label></b><u id='A1F1C8AA97'></u>
          <i id='A1F1C8AA97'><strike id='A1F1C8AA97'><tt id='A1F1C8AA97'><pre id='A1F1C8AA97'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:9
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi
          Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more

          At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

          BristolCEOChristopherBoernerBusinessWireviaAPSANFRANCISCO— ChristopherBoernerhasbeentheCEOofBristolM